Press Release

Astellas Appoints Kenji Yasukawa as President and CEO

- Yasukawa, who brings more than 30 years of experience in the pharmaceutical industry, succeeds Yoshihiko Hatanaka, who will become Chairman of the Board -

Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "the Company") today announced that its Board of Directors approved a change in its Representative Director, President and CEO as stated below.

1. Reason for Change

The changes below enable Astellas to vigorously pursue the new strategic plan, which is set to start in the fiscal year 2018, aiming to realize the Astellas' Vision of being on the forefront of healthcare change to turn innovative science into value for patients.

2. Changes of Representative Directors

(Name) Yoshihiko Hatanaka
(New Position) Representative Director, Chairman of the Board
(Current Position) Representative Director, President and CEO

(Name) Kenji Yasukawa
(New Position) Representative Director, President and CEO
(Current Position) Representative Director, Executive Vice President

3. Effective date of change:

April 1, 2018

(Reference)

- **Curriculum Vitae of new Representative Director, Chairman of the Board**

  Name: Yoshihiko Hatanaka
  Date of Birth: April 20, 1957
  Place of Birth: Shizuoka prefecture

  -Carrier History

June 2011	Representative Director, President & CEO, the Company (present post)
April 2009	Senior Corporate Executive, Chief Strategy Officer and Chief Financial Officer, the Company
June 2008	Senior Corporate Executive of the Company and President & CEO, Astellas US LLC and President & CEO, Astellas Pharma US, Inc.
April 2006	Corporate Executive of the Company and President & CEO, Astellas US LLC and President & CEO, Astellas Pharma US, Inc.
June 2005	Corporate Executive, Vice President, Corporate Planning, Corporate Strategy Division, the Company
April 2005	Vice President, Corporate Planning, Corporate Strategy Division, the Company
April 2003	Director, Corporate Planning, Fujisawa Pharmaceutical Co., Ltd.
April 1980	Joined Fujisawa Pharmaceutical Co., Ltd.

  -Education

March 1980	Hitotsubashi University Bachelor of Economics

- **Curriculum Vitae of new Representative Director, President and CEO**

  Name: Kenji Yasukawa
  Date of Birth: June 7, 1960
  Place of Birth: Tokyo

  -Carrier History

June 2017	Representative Director, Executive Vice President, Chief Strategy Officer and Chief Commercial Officer, the Company (present post)
April 2017	Senior Corporate Executive, Senior Vice President, Chief Strategy Officer and Chief Commercial Officer, the Company
June 2012	Senior Corporate Executive, Senior Vice President and Chief Strategy Officer, the Company
April 2012	Corporate Executive, Senior Vice President and Chief Strategy Officer, the Company
April 2011	Corporate Executive, Vice President, Product & Portfolio Strategy, the Company
October 2010	Corporate Executive of the Company, Therapeutic Area Head, Urology, Astellas Pharma Global Development, Inc.
June 2010	Corporate Executive of the Company, Therapeutic Area Head, Urology, Astellas Pharma Europe B.V.
April 2005	Vice President, Project Management, Urology, the Company
April 1986	Joined the Company (former Yamanouchi Pharmaceutical Co., Ltd.)

  -Education

July 2001	Showa University Graduate School of Pharmaceutical Sciences, Japan, Ph.D. in Pharmaceutical Sciences
March 1986	University of Tokyo, Master of Science, Agriculture

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473